

Published in final edited form as:

Tetrahedron Lett. 2012 April 18; 53(16): 2096–2099. doi:10.1016/j.tetlet.2012.02.041.

Solid Phase Synthesis of Isoxazole and Isoxazoline-carboxamides *via* [2+3]-Dipolar Cycloaddition Using Resin-bound Alkynes or Alkenes

Sureshbabu Dadiboyena¹ and Adel Nefzi^{1,2,*}

¹Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway Port St. Lucie FL 34987 USA

²Florida Atlantic University, Boca Raton, FL 33431, USA

Abstract

An efficient approach for the parallel solid phase synthesis of isoxazole and isoxazoline derivatives has been developed. The isoxazoles and isoxazolines were constructed through a 1,3-dipolar cycloaddition reaction of nitrile oxides, with resin-bound alkynes or alkenes. The cycloaddition reaction conditions performed on solid phase supports was optimized, and an array of resin bound carboxylic acid building blocks were utilized for distinct conversions. This methodology presents a new alternative to the diversity oriented synthesis of disubstituted isoxazoles and isoxazolines different from existing routes which are limited in structural diversity

Keywords

Isoxazoles; Isoxazolines; Heterocycles; 1,3-Dipolar cycloadditions; Solid-phase synthesis; Combinatorial chemistry

Heterocycles display an array of significant bioactive properties,^{1–3} and heterocyclic scaffolds are present in a wide variety of drugs as well as drug like molecules of pharmaceutical relevance.^{4,5} Among the family of heterocyclic compounds, isoxazoles and isoxazolines are an important class of heterocycles displaying a wide variety of biological properties including antiviral,⁶ antitubulin,⁷ as well as anti-inflammatory activity.⁸ The synthesis of this family of heterocycles continue to attract the attention of synthetic organic and medicinal chemists.⁹ The isoxazoline framework is a prevalent feature of several natural products **1–6**,^{10,11} and the isoxazole structural motif is found in the COX II inhibitors, bextra **7** and parecoxib **8** (Fig.1).^{9a,12} A plethora of methodologies exist toward the synthesis of isoxazoles and isoxazolines,^{13,14} and most of them endeavor nitrile oxide cycloaddition (NOC) as a key step.¹⁵

On the other hand, combinatorial chemistry and high-throughput screening have changed the scale on which drug discovery programs are carried out.^{4,5} The inherent potential of this technique aid to accelerate the drug discovery process through rapid synthesis and

© 2012 Elsevier Ltd. All rights reserved.

Corresponding author: Ph: +1(772) 345 4739; Fax: +1(772) 345 3649; anefzi@tpims.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

subsequent screening of much larger numbers of compounds than previously possible.¹⁶ The versatile and potential capability afforded by the tea-bag approach,¹⁷ has led to the isolation and recognition of an array of bioactive peptides, including antibacterials, antigenic peptides, opioid receptor agonists and antagonists, inhibitors and several heterocyclic compounds of biomedical importance.¹⁸ In continuation of our research investigation toward the design, and development of novel heterocycles, we developed a parallel solid-phase nitrile oxide cycloaddition (NOC) strategy to synthesize a variety of isoxazoles and isoxazolines utilizing 1,3-dipolar cycloaddition chemistry.^{9,15} The hydroximoyl chlorides **11** for the 1,3-dipolar cycloaddition are not commercially available and were conveniently synthesized in two steps utilizing solution phase chemistry.^{8,9a} This methodology presents a new alternative to the diversity oriented synthesis of disubstituted isoxazoles and isoxazolines different from existing routes which, are limited in structural diversity.^{19,20}

We envisioned the synthesis of isoxazole **9** and isoxazolines **10** *via* 1,3-dipolar cycloaddition of *in situ* generated nitrile oxides with alkyne **12** or alkenes **13**. The required alkyne and alkene precursors are synthesized from the corresponding resin-bound carboxylic acid. The retrosynthetic rationale for the parallel solid-phase synthesis of isoxazoles and isoxazolines is illustrated in Scheme 1.

The parallel solid phase synthesis of all compounds were carried out utilizing Houghten's tea-bag approach, wherein the resin is packed within sealed polypropylene mesh packets.¹⁷ The first position of diversity was introduced by coupling several carboxylic acids to *p*-methylbenzhydrylamine resin. The generated secondary amide **14** was then alkylated in the presence of lithium *t*-butoxide and an alkylating agent (allyl bromide or propargyl bromide).²¹ The parallel synthesis of the resin-bound isoxazoles **9** and isoxazolines **10** was initiated by the nitrile oxide cycloaddition of the resin-bound alkynes and alkene derivatives. Structurally diverse combinations of carboxylic acids (cyclopentanecarboxylic acid, 1-cyclopenteneacetic acid, benzoic acid, 2-nitrobenzoic acid, piperonylic acid, syringyl, 4-biphenylcarboxylic acid, 1-naphthalenecarboxylic, diphenylacetic acid, 1-phenyl-1-cyclopropylcarboxylic acid, and 1-phenyl-1-cyclopentanecarboxylic acid) were selected.

To investigate the feasibility of nitrile oxide cycloadditions (NOC) on solid support, three different hydroximoyl chlorides were freshly prepared and were treated with triethylamine to generate the corresponding nitrile oxides.^{9,13c,f,14i,5a,b} Treatment of resin-bound dipolarophiles **12,13** with the generated nitrile oxides proceeded in a 1,3-dipolar fashion and furnished diversified isoxazoles and isoxazolines.²² In case of resin coupled with piperonylic acid, we also observed the formation of a diol (partially cleaved protected diol) in addition to the main product. All of the cycloadditions occurred in good yields and were isolated in high purities (Table 1 and 2). The protocol for the parallel synthesis of structurally diverse isoxazoles and isoxazolines is outlined in Scheme 2.

In conclusion, we have developed an efficient parallel solid-phase methodology to construct diversity oriented isoxazoles and isoxazolines *via* 1,3-dipolar cycloaddition reaction.²² Coupling of carboxylic acids to the resin introduced the first position of diversity which, following *N*-alkylation with allyl bromide or propargyl bromide furnished several resin-bound alkenes and alkynes. 1,3-Dipolar cycloaddition of the resin bound alkenes or alkynes with nitrile oxides led to the formation of the corresponding disubstituted isoxazole and isoxazolines.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank the State of Florida Funding, NIH (1R03DA025850-01A1, Nefzi; 5P41GM081261-03, Houghten; 3P41GM079590-03S1, Houghten) for providing generous financial support.

References

1. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC. *J Med Chem.* 1997; 40:1347. [PubMed: 9135032]
2. (a) Bhat GA, Montero JLG, Panzica RP, Wotring LL, Townsend LB. *J Med Chem.* 1981; 24:1165. [PubMed: 7328577] (b) Petrie CR III, Cottam HB, McKernan PA, Robins RK, Revankar GR. *J Med Chem.* 1985; 28:1010. [PubMed: 4020823]
3. (a) Elguero, J. *Comprehensive Heterocyclic Chemistry II.* Katrizky, AR.; Rees, CW.; Scriven, EFV., editors. Vol. 3. Pergamon; Oxford: 1996. p. 1(b) Patel JB, Malick JB, Salama AI, Goldberg ME. *Pharmacol Biochem And Behavior.* 1985; 23:675.
4. (a) Meng L, Lorsbach BA, Sparks TC, Fettinger JC, Kurth MJ. *J Comb Chem.* 2010; 12:129. [PubMed: 20000375] (b) Nefzi A, Ostresh JM, Houghten RA. *Chem Rev.* 1997; 97:449. [PubMed: 11848878] (c) Horton DA, Bourne GT, Smythe ML. *Chem Rev.* 2003; 103:893. [PubMed: 12630855]
5. (a) Nefzi A, Ostresh JM, Yu J, Houghten RA. *J Org Chem.* 2004; 69:3603. [PubMed: 15152987] (b) Gallop MA, Barret RW, Dower WJ, Fodor SPA, Gordon EM. *J Med Chem.* 1994; 37:1385. [PubMed: 8182695] (c) Thompson LA, Ellman JA. *Chem Rev.* 1996; 96:555. [PubMed: 11848765] (d) Dadiboyena S, Nefzi A. *Tetrahedron Lett.* 2011; 52:7030. [PubMed: 22199408]
6. (a) Lee YS, Kim BH. *Bioorg Med Chem Lett.* 2002; 12:1395. [PubMed: 11992785] (b) Srivastava S, Bajpai LK, Batra S, Bhaduri AP, Maikhuri JP, Gupta G, Dhar JD. *Bioorg Med Chem.* 1999; 7:2607. [PubMed: 10632071]
7. (a) Simoni D, Grisolia G, Giannini G, Roberti M, Rondanin R, Piccagli L, Baruchello R, Rossi M, Romagnoli R, Invidiata FP, Grimaudo S, Jung MK, Hamel E, Gebbia N, Crosta L, Abbadessa V, Di Cristina A, Dusonchet L, Meli M, Tolomeo M. *J Med Chem.* 2005; 48:723. [PubMed: 15689156] (b) Kaffy J, Pontikis R, Carrez D, Croisy A, Monneret C, Florent JC. *Bioorg Med Chem.* 2006; 14:4067. [PubMed: 16510288]
8. Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K. *J Med Chem.* 2000; 43:775. [PubMed: 10715145]
9. (a) Dadiboyena S, Xu J, Hamme AT II. *Tetrahedron Lett.* 2007; 48:1295. [PubMed: 18265873] (b) Dadiboyena S, Nefzi A. *Eur J Med Chem.* 2010; 45:4697. [PubMed: 20724040]
10. (a) Berquist, PR.; Wells, RJ. *Chemotaxonomy of the Porifera: The Development and Current Status of the Field.* In: Scheuer, PJ., editor. *Marine Natural Products: Chemical and Biological Perspectives.* Vol. 5. Academic Press; New York: 1993. p. 1-50.(b) Faulkner DJ. *Nat Prod Rep.* 1998;113. [PubMed: 9586223] (c) Faulkner DJ. *Nat Prod Rep.* 1997:259.
11. (a) Faulkner J. *Nat Prod Rep.* 2001; 18:1. [PubMed: 11245399] (b) Boehlow TR, Spilling CD. *Nat Prod Lett.* 1995; 7:1.(c) Faulkner JD. *Nat Prod Rep.* 2002; 19:1. [PubMed: 11902436] (d) Encarnacion RD, Sandoval E, Malmstrom J, Christophersen C. *J Nat Prod.* 2000; 63:874. [PubMed: 10869226] (e) Kernan MR, Canbie RC, Bergquist PR. *J Nat Prod.* 1990; 53:615.(f) Compagnone RS, Avila R, Suarez AI, Abrams OV, Rangel HR, Arvelo F, Pina IC, Merentes E. *J Nat Prod.* 1999; 62:1443. [PubMed: 10543914]
12. (a) Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K. *J Med Chem.* 2000; 43:1661. [PubMed: 10794682] (b) Dadiboyena S, Nefzi A. *Eur J Med Chem.* 2011; 46:5258. [PubMed: 21978837] (c) Toyokuni T, Dileep Kumar JS, Walsh JC, Shapiro A, Talley JJ, Phelps ME, Herschman HR, Barrio JR, Satyamurthy N. *Bioorg Med Chem Lett.* 2005; 15:4699. [PubMed: 16153836] (d) Sandanayaka VP, Youjun Y. *Org Lett.* 2000; 2:3087. [PubMed: 11009352]
13. For isoxazoles, see: Waldo JP, Larock RC. *Org Lett.* 2005; 23:5203. [PubMed: 16268538] Bourbeau MP, Rider JT. *Org Lett.* 2006; 8:3679. [PubMed: 16898790] Moore JE, Davies MW,

- Goodenough KM, Wybrow RAJ, York M, Johnson CN, Harrity JPA. *Tetrahedron*. 2005; 61:6707. Cecchi L, De Sarlo F, Machetti F. *Eur J Org Chem*. 2006:4852. Grecian S, Fokin VV. *Angew Chem, Int Ed*. 2008; 47:8285. Crossley JA, Browne DL. *J Org Chem*. 2010; 75:5414. [PubMed: 20608670] Lee CC, Fitzmaurice RJ, Caddick S. *Org Biomol Chem*. 2009; 7:4349. [PubMed: 19830280]
14. For isoxazoline natural products, see: Goldenstein K, Fendert T, Proksch P, Winterfeldt E. *Tetrahedron*. 2000; 56:4173. Harburn JJ, Rath NP, Spilling CD. *J Org Chem*. 2005; 70:6398. [PubMed: 16050702] Adamo MFA, Donati D, Duffy EF, Sarti-Fantoni P. *J Org Chem*. 2005; 70:8395. [PubMed: 16209583] Marsini MA, Huang Y, Van De Water R, Pettus TRR. *Org Lett*. 2007; 9:3229. [PubMed: 17645344] Wasserman HH, Wang J. *J Org Chem*. 1998; 63:5581. Boehlow TR, Harburn JJ, Spilling CD. *J Org Chem*. 2001; 66:3111. [PubMed: 11325276] Masatoshi M, Yamada K, Hoshino O. *Tetrahedron*. 1996:14713. Ogamino T, Nishiyama S. *Tetrahedron*. 2003; 59:9419. Bardhan S, Schmitt DC, Porco JA Jr. *Org Lett*. 2006; 8:927. [PubMed: 16494476]
15. Huisgen R. *Angew Chem Intl Ed*. 1963; 2:565. Huisgen R. *Angew Chem Intl Ed*. 1963; 2:633. For more examples, see: Dadiboyena S, Valente EJ, Hamme AT II. *Tetrahedron Lett*. 2010; 51:1341. [PubMed: 20161634] Dadiboyena S, Hamme AT II. *Tetrahedron Lett*. 2011; 52:2536. [PubMed: 21686095] Dadiboyena S, Valente EJ, Hamme AT II. *Tetrahedron Lett*. 2009; 50:291. [PubMed: 20098488]
16. Yu, Y.; Nefzi, A.; Ostresh, JM.; Houghten, RA. *Innovations and Perspectives in Solid Phase Synthesis and Combinatorial Libraries*. Epton, Roger, editor. Mayflower Worldwide Ltd; London UK: 2004.
17. Houghten RA. *Proc Natl Acad Sci USA*. 1985; 82:5131. [PubMed: 2410914]
18. (a) Houghten RA, Wilson DB, Pinilla C. *Drug Discovery Today*. 2000; 5:276. [PubMed: 10856909] (b) Houghten RA, Pinilla C, Appel JR, Blondelle SE, Dooley CT, Eichler J, Nefzi A, Ostresh JM. *J Med Chem*. 1999; 42:3743. [PubMed: 10508425]
19. (a) Sammelson RE, Miler RB, Kurth MJ. *J Org Chem*. 2000; 65:2225. [PubMed: 10774051] (b) Jeddeloh MR, Holden JB, Nouri DH, Kurth MJ. *J Comb Chem*. 2007; 9:1041. [PubMed: 17910514]
20. (a) Shankar BB, Yang DY, Ganguly AK. *Tetrahedron Lett*. 1998; 39:2447. (b) Curran DP, Choi S-M, Gothe SA, Lin F-T. *J Org Chem*. 1990; 55:3710.
21. (a) Ostresh JM, Schoner CC, Hamashin VT, Nefzi A, Meyer JP, Houghten RA. *J Org Chem*. 1998; 63:8622. (b) Do Erner B, Husar GM, Ostresh JM, Houghten RA. *Bioorg Med Chem*. 1996; 4:709. [PubMed: 8804537] (c) Nefzi A, Ostresh JM, Houghten RA. *Tetrahedron*. 1999; 55:335.
22. *General procedure for the 1,3-Dipolar cycloaddition*: Resin-bound carboxylic acid coupling and *N*-alkylation using allyl bromide or propargyl bromide were performed according to the literature precedents.²¹ Resin-bound alkyne (alkene) and the hydroximoyl chloride (10 equiv.) in 10 mL of dry dichloromethane (DCM) was treated with triethylamine (0.16 mL, 10 equiv) and the reaction mixture was stirred overnight. The excess solution was decanted, and the resin was washed with DCM (2 x 5 mL). The resin was cleaved with anhydrous HF (10 mL) for 90 min at 0 °C, and the desired isoxazole (isoxazoline) was obtained following extraction with 95% AcOH in H₂O and lyophilization as a colorless powder. The isoxazole (isoxazoline) was purified by preparative reverse-phase HPLC; *Cyclopentanecarboxylic acid (3-phenyl-isoxazol-5-ylmethyl)-amide* (15b): ¹H NMR (500 MHz; DMSO-*d*₆): δ 1.50–1.52 (m, 2H), 1.61–1.67 (m, 4H), 1.77–1.79 (m, 2H), 2.61–2.64 (m, 1H), 4.44 (d, *J* = 6.0 Hz, 2H), 6.81 (s, 1H), 7.49–7.52 (m, 3H), 7.84–7.87 (m, 2H), 8.49 (t, *J* = 6.0 Hz, 1H); MS (ESI) *m/z* calcd for C₁₆H₁₈N₂O₂ [M+H⁺]: 270.3; found: 271.4; *Benzo[1,3]dioxole-5-carboxylic acid (3-biphenyl-4-yl-isoxazol-5-ylmethyl)-amide* (15i): ¹H NMR (500 MHz; DMSO-*d*₆): δ 1.23 (s, 2H), 4.64 (d, *J* = 5.5 Hz, 2H), 6.55 (s, 1H), 7.02 (d, *J* = 8.0 Hz, 1H), 7.41 (t, *J* = 7.0 Hz, 1H), 7.45 (s, 1H), 7.50 (q, *J* = 8.0 Hz, 3H), 7.74 (d, *J* = 8.5 Hz, 2H), 7.80 (d, *J* = 8.5 Hz, 2H), 7.97 (d, *J* = 8.0 Hz, 2H), 9.07 (t, *J* = 6.0 Hz, 1H); MS (ESI) *m/z* calcd for C₂₄H₁₈N₂O₄ [M+H⁺]: 398.4; found: 399.3; *Cyclopentanecarboxylic acid (3-biphenyl-4-yl-isoxazol-5-ylmethyl)-amide* (15j): ¹H NMR (500 MHz; DMSO-*d*₆): δ 1.23 (s, 4H), 1.50–1.52 (m, 1H), 1.63–1.68 (m, 2H), 1.77–1.80 (m, 1H), 2.62–2.65 (m, 1H), 4.46 (t, *J* = 5.8 Hz, 2H), 6.88 (s, 1H), 7.41 (t, *J* = 7.2 Hz, 1H), 7.50 (t, *J* = 8.0 Hz, 2H), 7.74 (t, *J* = 9.5 Hz, 2H), 7.81 (t, *J* = 8.1 Hz, 2H), 7.95 (t, *J* = 10.5 Hz, 2H), 8.49–8.51 (m, 1H); MS (ESI) *m/z* calcd for C₂₂H₂₂N₂O₂ [M+H⁺]: 346.4; found: 347.4; *Benzo[1,3]dioxole-5-carboxylic acid [3-(2,6-dichloro-phenyl)-isoxazol-5-*

ylmethyl]-amide (15s): $^1\text{H NMR}$ (500 MHz; $\text{DMSO-}d_6$): δ 4.69 (d, $J = 5.5$ Hz, 2H), 6.10 (s, 2H), 6.59 (s, 1H), 7.01 (d, $J = 8.5$ Hz, 1H), 7.43 (s, 1H), 7.50 (d, $J = 10.0$ Hz, 1H), 7.54–7.63 (m, 1H), 7.64–7.65 (m, 2H), 9.1 (t, $J = 5.5$ Hz, 1H); MS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{12}\text{Cl}_2\text{N}_2\text{O}_4$ [$\text{M}+\text{H}^+$]: 391.2; found: 393.2; *Biphenyl-4-carboxylic acid [3-(2,6-dichloro-phenyl)-isoxazol-5-ylmethyl]-amide* (15w): $^1\text{H NMR}$ (500 MHz; $\text{DMSO-}d_6$): δ 4.75 (d, $J = 4.5$ Hz, 2H), 6.62 (s, 1H), 7.41 (m, 1H), 7.50 (t, $J = 7.0$ Hz, 2H), 7.56 (t, $J = 8.0$ Hz, 1H), 7.64 (t, $J = 8.5$ Hz, 2H), 7.74 (d, $J = 8.5$ Hz, 2H), 7.80 (d, $J = 8.5$ Hz, 2H), 8.01 (d, $J = 8.5$ Hz, 2H), 9.31 (t, $J = 6.0$ Hz, 2H); MS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{16}\text{Cl}_2\text{N}_2\text{O}_2$ [$\text{M}+\text{Na}^+$]: 423.2; found: 446.1; *Cyclopentanecarboxylic acid (3-phenyl-4,5-dihydro-isoxazol-5-ylmethyl)-amide* (16a): $^1\text{H NMR}$ (500 MHz; $\text{DMSO-}d_6$): δ 1.44–1.68 (m, 8H), 2.54 (t, $J = 7.5$ Hz, 1H), 3.13 (dd, $J = 7.0$ Hz, 17 Hz 1H), 3.22–3.24 (m, 1H), 3.44 (dd, $J = 11.0$ Hz, 17 Hz 1H), 4.72–4.78 (m, 1H), 7.43–7.46 (m, 3H), 7.62–7.65 (m, 2H), 8.04 (t, $J = 6.0$ Hz, 1H); MS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{16}\text{Cl}_2\text{N}_2\text{O}_2$ [$\text{M}+\text{H}^+$]: 272.3; found: 273.1; *Benzo[1,3]dioxole-5-carboxylic acid (3-biphenyl-4-yl-4,5-dihydro-isoxazol-5-ylmethyl)-amide* (16f): $^1\text{H NMR}$ (500 MHz; $\text{DMSO-}d_6$): δ 3.40 (dd, $J = 7$ Hz, 17.5 Hz, 1H), 3.61–3.70 (m, 1H), 3.77–3.81 (m, 1H), 4.34 (dd, $J = 5.5$ Hz, 12 Hz, 1H), 4.43 (dd, $J = 3.5$ Hz, 12 Hz, 1H), 5.07–5.13 (m, 1H), 6.11 (s, 2H), 6.80–6.82 (m, 1H), 6.98–7.00 (m, 2H), 7.09–7.10 (m, 1H), 7.32 (s, 1H), 7.40–7.42 (m, 1H), 7.48–7.54 (m, 4H), 7.72–7.74 (m, 2H); MS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_4$ [$\text{M}+\text{Na}^+$]: 400.4; found: 423.2; *Cyclopentanecarboxylic acid (3-biphenyl-4-yl-4,5-dihydro-isoxazol-5-ylmethyl)-amide* (16g): $^1\text{H NMR}$ (500 MHz; $\text{DMSO-}d_6$): δ 1.45–1.69 (m, 6H), 2.55–2.58 (m, 1H), 3.15–3.19 (m, 1H), 3.24–3.32 (m, 1H), 3.46–3.51 (m, 1H), 4.74–4.80 (m, 1H), 7.4 (t, $J = 8.0$ Hz, 1H), 7.49 (t, $J = 7.5$ Hz, 2H), 7.71–7.73 (m, 4H), 7.77–7.78 (m, 2H), 8.05 (t, $J = 6.0$ Hz, 1H); MS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_2$ [$\text{M}+\text{H}^+$]: 348.4; found: 349.3; *N-[3-(2,6-Dichloro-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-2-nitro-benzamide* (16r): $^1\text{H NMR}$ (500 MHz; $\text{DMSO-}d_6$): δ 3.14 (dd, $J = 6.5$ Hz, 17.5 Hz, 1H), 3.41–3.55 (m, 3H), 4.96–5.00 (m, 1H), 7.52–7.55 (m, 1H), 7.61–7.64 (m, 3H), 7.8 (t, $J = 7.5$ Hz, 1H), 8.05 (d, $J = 10$ Hz, 1H), 9.06 (t, $J = 6.0$ Hz, 1H); MS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{13}\text{Cl}_2\text{N}_3\text{O}_4$ [$\text{M}+\text{Na}^+$]: 394.20; found: 417.1; *Benzo[1,3]dioxole-5-carboxylic acid [3-(2,6-dichloro-phenyl)-4,5-dihydro-isoxazol-5-ylmethyl]-amide* (16s): $^1\text{H NMR}$ (500 MHz; $\text{DMSO-}d_6$): δ 3.14 (dd, $J = 6.5$ Hz, 17.5 Hz, 2H), 3.64–3.48 (m, 2H), 3.55–3.61 (m, 1H), 4.98–5.0 (m, 1H), 6.1 (s, 2H), 6.99 (d, $J = 10$ Hz, 2H), 7.43 (s, 1H), 7.48–7.58 (m, 2H), 7.60 (d, $J = 5.0$ Hz, 2H), 8.65 (t, $J = 6.0$ Hz, 1H); MS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{14}\text{Cl}_2\text{N}_2\text{O}_4$ [$\text{M}+\text{Na}^+$]: 393.22; found: 417.2






Figure 1.
Naturally occurring isoxazolines and pharmaceutically relevant isoxazoles.



Scheme 1.
Retrosynthetic illustration of structurally diverse isoxazoles and isoxazolines.



Reagents and Conditions: (a) t BuOLi, DMSO, 5h; (b) $(C_2H_5)_3N$, CH_2Cl_2 , r.t. overnight; (c) anhydrous HF, 90 min, $0^\circ C$

Scheme 2.

Solid phase synthesis of structurally diverse isoxazoles and isoxazolines

Table 1

Isoxazoles from resin-bound alkynes

Entry	R ₁	R ₂	Mass calcd./found	Yields (%) ^a
15a	Piperonyl	H	322.3/323.2 (MH ⁺)	87
15b	Cyclopentyl	H	270.3/271.4 (MH ⁺)	66
15c	1-Cyclopenteneacetyl	H	282.3/283.2 (MH ⁺)	91
15d	4-Biphenyl	H	354.4/355.2 (MH ⁺)	63
15e	Syringyl	H	354.4/356.0 (MH ⁺)	54
15f	1-Phenyl-1-cyclopropyl	H	318.3/319.6 (MH ⁺)	52
15g	Diphenylacetyl	H	368.4/369.5 (MH ⁺)	75
15h	Phenyl	4-Ph	354.4/355.2 (MH ⁺)	90
15i	Piperonyl	4-Ph	398.4/399.3 (MH ⁺)	83
15j	Cyclopentyl	4-Ph	346.4/347.4 (MH ⁺)	93
15k	1-Cyclopenteneacetyl	4-Ph	358.4/359.2 (MH ⁺)	94
15l	2-Nitrophenyl	4-Ph	399.4/400.4 (MH ⁺)	55
15m	4-Biphenyl	4-Ph	430.5/431.4 (MH ⁺)	63
15n	1-Phenyl-1-cyclopropyl	4-Ph	394.5/395.3 (MH ⁺)	75
15o	Diphenylacetyl	4-Ph	444.5/445.3 (MH ⁺)	62
15p	Syringyl	4-Ph	430.4/453.2 (MH ⁺)	63
15q	1-Naphthyl	4-Ph	404.5/405.4 (MH ⁺)	73
15r	2-Nitrophenyl	2,6-diCl	392.2/393.5 (MH ⁺)	70
15s	Piperonyl	2,6-diCl	391.2/392.4 (MH ⁺)	91
15t	Phenyl	2,6-diCl	347.4/349.3 (MH ⁺)	92
15u	Cyclopentyl	2,6-diCl	415.4/416.3 (MH ⁺)	79
15v	1-Phenyl-1-cyclopentyl	2,6-diCl	415.3/438.2 (MNa ⁺)	75
15w	4-Biphenyl	2,6-diCl	423.3/446.1 (MNa ⁺)	86

The products were run on a Vydac column, gradients 5 to 95% formic acid in Acetonitrile in 7 min.

^aThe yields are based on the weight of purified products and are relatives to the initial loading of the resin. (The purity of the purified compounds is higher than 95% for all the compounds).

Table 2

Isoxazolines from resin-bound alkenes

Entry	R ₁	R ₂	Mass calcd./found	Yields (%) ^a
16a	Cyclopentyl	H	272.3/273.1 (MH ⁺)	96
16b	1-Cyclopenteneacetyl	H	284.1/285.1 (MH ⁺)	92
16c	4-Biphenyl	H	356.4/357.3 (MH ⁺)	67
16d	1-Phenyl-1-cyclopropyl	H	320.3/321.2 (MH ⁺)	87
16e	Syringyl	H	356.3/357.2 (MH ⁺)	77
16f	Piperonyl	4-Ph	400.4/423.2 (MNa ⁺)	63
16g	Cyclopentyl	4-Ph	348.4/349.3 (MH ⁺)	93
16h	1-Cyclopenteneacetyl	4-Ph	360.4/361.3 (MH ⁺)	88
16i	2-Nitrophenyl	4-Ph	401.5/402.4 (MH ⁺)	84
16j	Phenyl	4-Ph	356.3/357.3 (MH ⁺)	84
16k	1-Phenyl-1-cyclopropyl	4-Ph	396.5/397.4 (MH ⁺)	77
16l	Diphenylacetyl	4-Ph	446.4/447.4 (MH ⁺)	82
16m	Syringyl	4-Ph	432.4/433.2 (MH ⁺)	87
16n	1-Naphthyl	4-Ph	406.5/429.3 (MNa ⁺)	71
16o	4-Biphenyl	4-Ph	432.5/455.5 (MNa ⁺)	61
16p	1-Phenyl-1-cyclopentyl	4-Ph	424.5/447.3 (MNa ⁺)	72
16q	Phenyl	2,6-diCl	349.2/372.3 (MNa ⁺)	96
16r	2-Nitrophenyl	2,6-diCl	394.2/417.1 (MNa ⁺)	95
16s	Piperonyl	2,6-diCl	393.2/417.2 (MNa ⁺)	96
16t	Cyclopentyl	2,6-diCl	417.3/440.2 (MNa ⁺)	87
16u	1-Phenyl-1-cyclopentyl	2,6-diCl	417.3/440.1 (MNa ⁺)	77
16v	4-Biphenyl	2,6-diCl	425.3/447.4 (MNa ⁺)	78

The products were run on a Vydac column, gradients 5 to 95% formic acid in Acetonitrile in 7 min.

^aThe yields are based on the weight of purified products and are relatives to the initial loading of the resin (The purity of the purified compounds is higher than 95% for all the compounds).